Bristol-Myers Squibb (BMY)

In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and market analysts alike. While the specifics of such an event remain a forward-looking conjecture, this article delves into the potential

Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This notable drop came on the heels of the company's announcement and pricing of a substantial public stock offering, a move that

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025. These new duties, targeting sectors from pharmaceuticals to heavy trucks and home furnishings, signal a deepening

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

Bristol Myers Squibb reported positive Phase 3 results for iberdomide in multiple myeloma; analysts eye CELMoDs as key to future growth.

Find out why investors seeking passive income want shares of this dividend payer in their portfolio.

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet medical needs. From a groundbreaking FDA approval for bladder cancer to promising Phase 3 results for a next-generation psoriasis treatment and a

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca (pirtobrutinib). Olomorasib recently secured a coveted Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for

The fate of a once-promising cancer treatment now looks uncertain at best.

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

Quality yields above 6% from three very different market sectors.

Bristol-Myers Squibb (BMY) offers a compelling 5.22% dividend yield with a strong history of growth, backed by high profitability and an attractive valuation.

The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high unemployment, and persistent inflation. This peculiar confluence, which defies traditional economic models, is sending ripples of concern through financial markets and

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential winners in this booming sector.

With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward.

BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.

The S&P 500 index has repeatedly scaled new all-time highs in recent months, a testament to robust corporate earnings and an enduring wave of optimism, largely fueled by advancements in Artificial Intelligence. This remarkable ascent, however, has ignited a fervent debate among financial analysts: are we witnessing a healthy